References
1. Barrett JS, Fossler MJ, Cadieu KD,
Gastonguay MR. Pharmacometrics: a multidisciplinary field to facilitate
critical thinking in drug development and translational research
settings. J Clin Pharmacol 2008; 48: 632-49.
2. Ette EI, Williams PJ.
Pharmacometrics: the science of quantitative pharmacology: John Wiley &
Sons, 2013.
3. Liu D, Ma G, Xiang X, Liu J, Zhao
P, Chen R, Chen Y, Huang X, Li L, Li L, Nie J, Wang Y, Wei C, Lu W, Shi
J, Li G, Yang J, Wang Y, Zheng Q, Hu B. The value and general
consideration of pharmacometric study in new drug development. Chin J
Clin Pharmacol Ther 2018; 23: 961-73.
4. Asín-Prieto E, Rodríguez-Gascón A,
Isla A. Applications of the pharmacokinetic/pharmacodynamic (PK/PD)
analysis of antimicrobial agents. J Infect Chemother 2015; 21: 319-29.
5. Kitamura Y, Yoshida K, Kusama M,
Sugiyama Y. A proposal of a pharmacokinetic/pharmacodynamic (PK/PD)
index map for selecting an optimal PK/PD index from conventional indices
(AUC/MIC, Cmax/MIC, and TAM) for antibiotics. Drug Metab Pharmacokinet
2014; 29: 455-62.
6. Tunkel AR, Scheld. Aztreonam.
Infect Control Hosp Epidemiol 1990; 11: 486-94.
7. Zhang J. Clinical Pharmacology of
Antimicrobial Agents. In: Practical Anti Infective Therapy, 2013:
87-110.
8. Rizk M, Zou L, Savic R, Dooley KE.
Importance of drug pharmacokinetics at the site of action. Clin Transl
Sci 2017; 10: 133-42.
9. ICH. Efficacy Guidelines.
<https://www.ich.org/page/efficacy-guidelines>.
2020. Accessed February 17 2020.
10. FDA. Guidance for industry:
population pharmacokinetics. Rockville: US Food and Drug Administration
1999.
11. FDA. Exposure-Response
Relationships - Study Design, Data Analysis, and Regulatory
Applications.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/exposure-response-relationships-study-design-data-analysis-and-regulatory-applications>.
2003. Accessed December 1 2019.
12. FDA. Population Pharmacokinetics.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/population-pharmacokinetics>.
2019. Accessed February 2 2020.
13. EMA. Guideline on reporting the
results of population pharmacokinetic analyses.
<https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-results-population-pharmacokinetic-analyses_en.pdf>.
2007. Accessed February 16 2020.
14. EMA. Guideline on the use of
pharmacokinetics and pharmacodynamics in the development of
antimicrobial medicinal products.
<https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-use-pharmacokinetics-pharmacodynamics-development-antimicrobial-medicinal-products_en.pdf>.
2016. Accessed February 16 2020.
15. EMA. Guideline on the evaluation
of medicinal products indicated for treatment of bacterial infections.
<https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf>.
2018. Accessed February 16 2020.
16. EMA. Guideline on the evaluation
of the pharmacokinetics of medicinal products in patients with impaired
hepatic function (CPMP/EWP/2339/02).
<https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function_en.pdf>.
2005. Accessed February 16 2020.
17. EMA. Note for guidance on the
evaluation of the pharmacokinetics of medicinal products in patients
with impaired renal function (CHMP/EWP/225/02).
<https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-evaluation-pharmacokinetics-medical-products-patients-impaired-renal-function_en.pdf>.
2004. Accessed February 15 2020.
18. Ma G, Xu L, Chen R, Chen Y, Zhao
W, Liu D, Jiao Z, Li J, Ji S, Li L, Li L, Wang Y, Yang J, Wang Y, Sun H,
Hu B, Zheng Q, Wei L. General considerations of population
pharmacokineticpharmacodyna-mic study in new drug development. Chin J
Clin Pharmacol Ther 2019; 24: 1201-20.
19. Sun R. Quantitative pharmacology:
Beijing: People’s Medical Publishing House, 1987.
20. Xie H. Quantitative Pharmacology
and Drug Development: People’s Military Medical Publishing House, 2011.
21. Zhang J, Lv Y, Yu K, Guan X,
Huang Y, Kang Y, Cui J, Liang B, Yang Y, Yan J. Expert Consensus on
Antibiotics Pharmacokinetics/Pharmacodynamics Clinical Application. Chin
J Tuber and Respir Dis 2018; 41: 409-46.
22. FDA. Challenge and opportunity on
the critical path to new medical products. http://www fda
gov/oc/initiatives/criticalpath/ 2004.
23. Vila J, Hebert AA, Torrelo A,
López Y, Tato M, García-Castillo M, Cantón R. Ozenoxacin: a review of
preclinical and clinical efficacy. Expert Rev Anti Infect Ther 2019; 17:
159-68.
24. Gupta AK, Simpson FC.
Efinaconazole (Jublia) for the treatment of onychomycosis. In: Taylor &
Francis, 2014.
25. McKeage K. Finafloxacin: first
global approval. Drugs 2015; 75: 687-93.
26. Chandorkar G, Xiao A, Mouksassi
MS, Hershberger E, Krishna G. Population pharmacokinetics of
ceftolozane/tazobactam in healthy volunteers, subjects with varying
degrees of renal function and patients with bacterial infections. J Clin
Pharmacol 2015; 55: 230-39.
27. Zhang L, Bhavnani SM, Ambrose PG,
Cammarata SK, Rubino CM. Population Pharmacokinetic (PPK) Analysis for
Intravenous (IV) and Oral (PO) Delafloxacin Using Data From Phase 1
Studies. Open Forum Infect Dis 2016; 3.
28. Trang M, Seroogy JD, Van Wart SA,
Bhavnani SM, Kim A, Gibbons JA, Ambrose PG, Rubino CM. Population
pharmacokinetic analyses for plazomicin using pooled data from phase 1,
2, and 3 clinical studies. Antimicrob Agents Chemother 2019; 63:
e02329-18.
29. Li J, Lovern M, Green ML, Chiu J,
Zhou D, Comisar C, Xiong Y, Hing J, MacPherson M, Wright JG.
Ceftazidime‐avibactam population pharmacokinetic modeling and
pharmacodynamic target attainment across adult indications and patient
subgroups. Clin Trans Sci 2019; 12: 151-63.
30. Desai A, Kovanda L, Kowalski D,
Lu Q, Townsend R, Bonate PL. Population pharmacokinetics of
isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and
target attainment in patients with invasive infections due to
Aspergillus and other filamentous fungi. Antimicrob Agents Chemother
2016; 60: 5483-91.
31. Rubino CM, Bhavnani SM, Loutit
JS, Morgan EE, White D, Dudley MN, Griffith DC. Phase 1 study of the
safety, tolerability, and pharmacokinetics of vaborbactam and meropenem
alone and in combination following single and multiple doses in healthy
adult subjects. Antimicrob Agents Chemother 2018; 62: e02228-17.
32. Van Wart SA, Forrest A, Khariton
T, Rubino CM, Bhavnani SM, Reynolds DK, Riccobene T, Ambrose PG.
Population pharmacokinetics of ceftaroline in patients with acute
bacterial skin and skin structure infections or community‐acquired
bacterial pneumonia. J Clin Pharmacol 2013; 53: 1155-67.
33. Buckwalter M, Dowell JA.
Population pharmacokinetic analysis of dalbavancin, a novel
lipoglycopeptide. J Clin Pharmacol 2005; 45: 1279-87.
34. Bhavnani SM, Passarell JA, Owen
JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetic-pharmacodynamic
relationships describing the efficacy of oritavancin in patients with
Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50:
994-1000.
35. Hong M-C, Hsu DI, Bounthavong M.
Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and
β-lactamase-inhibitor combination. Infect Drug Resist 2013; 6: 215-23.
36. Riccobene TA, Rekeda L, Rank D,
Llorens L. Evaluation of the effect of a supratherapeutic dose of
intravenous ceftaroline fosamil on the corrected QT interval. Antimicrob
Agents Chemother 2013; 57: 1777-83.
37. Theuretzbacher U, Ihle F,
Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole.
Clin Pharmacokinet 2006; 45: 649-63.
38. Trang M, Dudley MN, Bhavnani SM.
Use of Monte Carlo simulation and considerations for PK-PD targets to
support antibacterial dose selection. Curr Opin Pharmacol 2017; 36:
107-13.
39. Guo B, Wu X, Zhang Y, Shi Y, Yu
J, Cao G, Zhang J. Safety and clinical pharmacokinetics of nemonoxacin,
a novel non-fluorinated quinolone, in healthy Chinese volunteers
following single and multiple oral doses. Clin Drug Investig 2012; 32:
475-86.
40. EMA. Guideline on the Readability
of the Labelling and Package Leaflet of Medicinal Products for Human
Use. In: Revision, 2009.
41. FDA. Clinical Pharmacology
Labeling for Human Prescription Drug and Biological Products - Content,
and Format.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-labeling-human-prescription-drug-and-biological-products-content-and-format>.
2016. Accessed February 14 2020.
42. FDA. Clinical Studies Section of
Labeling for Human Prescription Drug and Biological Products - Content
and Format.
<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-studies-section-labeling-human-prescription-drug-and-biological-products-content-and-format>.
2006. Accessed February 14 2020.
Table 1 Summary of the antimicrobial agents approved by
FDA and EMA from January 2001 to May 2019